Towards responsible ctDNA-based multi-cancer screening: a preliminary exploration and discussion of ethically relevant aspects

Abstract

While testing for easily accessible biomarkers in the circulation (“liquid biopsy”) has found its way to clinical cancer care, a further expected development is its use as a “universal” early detection test in population screening for cancer. A promising marker for such screening is circulating cell-free fragments of tumor DNA, shed into the circulation during tumor cell turnover. Several blood-based “multicancer early detection (MCED) tests” have recently been developed - but still need validation in large-scale studies involving non-patient populations. In this paper, we proactively explore the ethical aspects of this development. We refer to an often quoted synthesis of the internationally accepted framework of principles for responsible screening as first drawn up for the World Health Organisation (WHO) by Wilson and Junger 50 years ago and further developed and fine-tuned ever since. As our analysis suggests, some specific ethical issues and concerns about potential MCED screening connect to the fact that cancer is not just one disease. As a consequence, not all findings will have the same clinical utility. We discuss this against the background of earlier debates pertaining to broad scope forms of screening in other contexts, specifically newborn and reproductive genetic screening. We highlight the guidance provided by some of the criteria from the screening framework that seems most relevant in this connection: the need for screening objectives to be defined at the outset, the need for mechanisms to minimize potential risks, and the requirement that, for those participating in the screening, the overall benefits outweigh the harm.

Keywords

Cancer / population screening / cfDNA / ctDNA / MCED / ethics / public health / screening criteria

References

[1] RIVM: National Institute for Public Health and the Environment. Population screening. Available from: https://www.bevolkingsonderzoeknederland.nl/en/ [Last accessed on 16 August 2022].

[2] Health Council of the Netherlands. Population Screening Act (WBO): pilot population screening for lung cancer. The Hague: Gezondheidsraad; 2021. Available from: https://www.healthcouncil.nl/documents/advisory-reports/2021/06/09/population-screening-act-wbo-pilot-population-screening-for-lung-cancer [Last accessed on 16 August 2022].

[3] Ahlquist DA.Universal cancer screening: revolutionary, rational, and realizable.NPJ Precis Oncol2018;2:23 PMCID:PMC6206005

[4] Perrier A,Guenoun A.Moving towards a personalized oncology: the contribution of genomic techniques and artificial intelligence in the use of circulating tumor biomarkers.Bull Cancer2022;109:170-84

[5] Cowling T.An overview of liquid biopsy for screening and early detection of cancer. In: CADTH Issues in Emerging Health Technologies. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016. 179.

[6] Gadsbøll K,Gatinois V.NIPT-map Study GroupCurrent use of noninvasive prenatal testing in Europe, Australia and the USA: a graphical presentation.Acta Obstet Gynecol Scand2020;99:722-30

[7] Wan JCM,Garcia-Corbacho J.Liquid biopsies come of age: towards implementation of circulating tumour DNA.Nat Rev Cancer2017;17:223-38

[8] Chen M.Next-generation sequencing in liquid biopsy: cancer screening and early detection.Hum Genomics2019;13:34 PMCID:PMC6669976

[9] Hackshaw A,Hartman AR.New genomic technologies for multi-cancer early detection: rethinking the scope of cancer screening.Cancer Cell2022;40:109-13

[10] Liu MC,Klein EA,Seiden MV.CCGA ConsortiumSensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.Ann Oncol2020;31:745-59 PMCID:PMC8274402

[11] Lennon AM,Kinde I.Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention.Science2020;369:eabb9601 PMCID:PMC7509949

[12] Hackshaw A,Reichert H,Chung KC.Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK.Br J Cancer2021;125:1432-42 PMCID:PMC8575970

[13] National Health Service. NHS to pilot potentially revolutionary blood test that detects more than 50 cancers. 27 November 2020. Available from: https://www.england.nhs.uk/2020/11/nhs-to-pilot-potentially-revolutionary-blood-test/ [Last accessed on 16 August 2022]

[14] NHS Galleri trial. Clinical resources for GPs. 05 August 2021. Available from: https://www.nhs-galleri.org/about-the-trial/clinical-resources [Last accessed on 16 August 2022]

[15] Cochrane AL.Validations of screening procedures.Br Med Bull1971;27:3-8

[16] Juth N. The Ethics of Screening in Health Care and Medicine: Serving Society or Serving the Patient? Dordrecht, Heidelberg, London, New York: Springer; 2012. Available from: https://link.springer.com/book/10.1007/978-94-007-2045-9 [Last accessed on 16 Aug 2022]

[17] Health Council of the Netherlands. Screening. Between hope and hype. The Hague: Gezondheidsraad; 2008. Available from: https://www.healthcouncil.nl/documents/advisory-reports/2008/04/01/screening-between-hope-and-hype [Last accessed on 16 August 2022].

[18] Gray JA,Blanks RG.Maximising benefit and minimising harm of screening.BMJ2008;336:480-3 PMCID:PMC2258553

[19] Haddow J.ACCE: a model process for evaluating data on emerging genetic tests. In: Khoury M, Little J, Burke W, editors. Human Genome Epidemiology: a scientific foundation for using genetic information to improve health and prevent disease. New York, Oxford: OUP; 2004. p. 217-33.

[20] Andermann A,Beauchamp S.Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years.Bull World Health Organ2008;86:317-9 PMCID:PMC2647421

[21] Serrano MJ,Diaz Mochon JJ.International Society of Liquid BiopsyPrecision prevention and cancer interception: the new challenges of liquid biopsy.Cancer Discov2020;10:1635-44

[22] Putcha G,Skates S.Multicancer screening: one size does not fit all.JCO Precis Oncol2021;5:574-6

[23] Cohen JD,Wang Y.Detection and localization of surgically resectable cancers with a multi-analyte blood test.Science2018;359:926-30 PMCID:PMC6080308

[24] Ezell S. Seizing the transformative opportunity of multi-cancer early detection: information technology & innovation foundation (ITIF); 2021. Available from: https://itif.org/publications/2021/04/19/seizing-transformative-opportunity-multi-cancer-early-detection [Last accessed on 16 August 2022]

[25] Burke W,Gwinn M.Genetic test evaluation: information needs of clinicians, policy makers, and the public.Am J Epidemiol2002;156:311-8

[26] Ozben T.Expanded newborn screening and confirmatory follow-up testing for inborn errors of metabolism detected by tandem mass spectrometry.Clin Chem Lab Med2013;51:157-76

[27] Jansen ME,Lister KJ.International differences in the evaluation of conditions for newborn bloodspot screening: a review of scientific literature and policy documents.Eur J Hum Genet2016;25:10-6 PMCID:PMC5159762

[28] der Meij KRM, Sistermans EA, Macville MVE, et al; Dutch NIPT Consortium. TRIDENT-2: national implementation of genome-wide non-invasive prenatal testing as a first-tier screening test in the Netherlands.Am J Hum Genet2019;105:1091-101

[29] Kirk EP,Boggs K.Gene selection for the Australian Reproductive Genetic Carrier Screening Project (“Mackenzie’s Mission”).Eur J Hum Genet2021;29:79-87 PMCID:PMC7852568

[30] Remec ZI,Repic Lampret B.Next-generation sequencing in newborn screening: a review of current state.Front Genet2021;12:662254 PMCID:PMC8188483

[31] Dondorp WJ.The “thousand-dollar genome”: an ethical exploration.Eur J Hum Genet2013;21 Suppl 1:S6-26 PMCID:PMC3660958

[32] Howard HC,Cornel MC,Sénécal K.European Society of Human Genetics, P3G International Paediatric Platform., Human Genome Organisation; and the PHG Foundation. Whole-genome sequencing in newborn screening?.Eur J Hum Genet2015;23:1593-600 PMCID:PMC4795188

[33] Johnston J,Goldenberg A,Parens E.members of the NSIGHT ethics and policy advisory boardSequencing newborns: a call for nuanced use of genomic technologies.Hastings Cent Rep2018;48 Suppl 2:S2-6 PMCID:PMC6901349

[34] Bailey DB Jr,Davis AM.Changing perspectives on the benefits of newborn screening.Ment Retard Dev Disabil Res Rev2006;12:270-9

[35] Alexander D.A vision of the future of newborn screening.Pediatrics2006;117:S350-4

[36] Dondorp W,Bombard Y.European Society of Human Genetics, American Society of Human Genetics. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening.Eur J Hum Genet2015;23:1438-50 PMCID:PMC4613463

[37] Loughry L,White M,Hui L.State-wide increase in prenatal diagnosis of klinefelter syndrome on amniocentesis and chorionic villus sampling: impact of non-invasive prenatal testing for sex chromosome conditions.Prenat Diagn2022;Online ahead of print:

[38] Donley G,Berkman BE.Prenatal whole genome sequencing: just because we can, should we?.Hastings Cent Rep2012;42:28-40 PMCID:PMC4113095

[39] Dondorp WJ,de Wert GM.Genomic futures of prenatal screening: ethical reflection.Clin Genet2016;89:531-8